Tuesday, March 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Antibiotic Resistant Bacteria Countermeasure Accelerator

by Global Biodefense Staff
February 23, 2016
Ebola Drug Research at UTMB

A new federal grant opportunity supporting a ‘Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator’ initiative has been issued by the U.S. Department of Health and Human Services Assistant Secretary for Preparedness and Response (HHS/ASPR).

The program is a novel collaborative model designed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline, and is a component of the National Strategy for Combating Antimicrobial Resistant Bacteria.

Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development.

This Accelerator for CARB will be focusing only on antibacterial products, working in tandem with the medical countermeasure accelerator efforts of Biomedical Advanced Research and Development Authority (BARDA) and National Institute of Allergy and Infectious Diseases (NIAID).

BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to Accelerator grant recipients.

Further details are available via Funding Opportunity Number: EP-IDS-16-001. The closing date for applications is April 15, 2016

Tags: AntimicrobialsASPRBARDAHHSMRSARequest for Proposals

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Liverpool Synthetic Biology Lab Backed By 2M Award
Policy + Initiatives

Political Interference: White House Launches Framework to Protect Scientific Integrity

January 13, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC